AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug. Skip to main content Friday 4 July 2025 . BlueSky linkedin ...

Imfinzi, which is used to treat some types of cancer, can cause side effects. Learn about common, mild, and serious side effects and how to manage them.

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.

The new indication allows durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...